Alexion Pharma: (NASD: ALXN)

$102.90

1.08 (1.06%)

Volume 977,654

May 17 04:00 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		101.77 - 104.29
	
		52wk Low - High
		81.82 - 119.54
	
		Previous Close
		101.82
	
		Avg. Volume
		1,765,227
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		20.09 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.47
	
		PE (Forward)
		38.58
	
		Current Year Est.
		2.67
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Outperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		91 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/10/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            38.58
                        
                            PEG Ratio
                            1.51
                        
                            Current Year Est.
                            2.67
                        
                            Current Quarter Estimate
                            0.60
                        
                            Most Accurate Estimate
                            0.60
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-24-2013
                        
                            EPS Last Year
                            2.06
                        
                            Expected Earnings Growth
                            25.52%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.   
Full ALXN Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ALXN Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.60	0.70	2.67	3.01
Number of Estimates	4	4	4	4
Low Estimate	0.58	0.67	2.60	2.86
High Estimate	0.62	0.72	2.71	NA
Year Ago EPS	0.41	0.53	1.86	2.67
EPS Growth	46.34%	32.55%	43.41%	12.65%

More ALXN Estimates

Average Earnings Estimates for ALXN

EPS Growth for ALXN

Industry Analysis

Name	Symbol	Previous Close
ALEXION PHARMA	ALXN	102.90
AETERNA ZENTARS	AEZS	2.10
ANIKA THERAPEUT	ANIK	14.40
GENTIUM SPA-ADR	GENT	8.87
AASTROM BIOSCI	ASTM	0.57
ACHILLION PHARM	ACHN	7.77
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.33
ALKERMES INC	ALKS	31.69
ALNYLAM PHARMA	ALNY	27.44

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Bayer's Xofigo Cleared in the US

May 16, 2013

Earnings Beat at Alexion, Ups View

Apr 25, 2013

Omeros' OMS721 Files for Orphan Drug Status

Apr 18, 2013

Bad News for Alexion, Shares Down

Apr 01, 2013

Alexion Pharma Upgraded to Outperform

Mar 15, 2013

Positive Data from BMRN's PKU-016

Feb 20, 2013

Update on Peregrine's Bavituximab

Feb 20, 2013

Alexion 4Q Tops on Both Lines

Feb 14, 2013

More ALXN Zacks Commentary

Financials

EPS TTM	2.06
Sales	1,134
Net Income	292
Price/Earnings	49.95
Price/Book	9.61
Price/Cash Flow	47.45
Price/Sales	16.35

More ALXN Financials

News

Potential Alexion Pharmaceuticals (ALXN) Trade Has 7.56% Downside Protection - Freshbrewedmedia

May 17, 2013

Alexion Pharmaceuticals Makes a Move: Up 2.3% - Financial News Network Online - Market Movers

May 14, 2013

Alexion Pharmaceuticals (ALXN) Trading Near $108.39 Resistance Level - Freshbrewedmedia

May 13, 2013

Short Interest in Vertex Rises, in Celgene Falls - Benzinga

May 11, 2013

Alexion Pharmaceuticals Bullish Moving Average Crossover Alert (ALXN) - Financial News Network Online - Moving Average Crossovers

May 9, 2013

Buyers Accumulate Shares of Alexion Pharmaceuticals, Up 2.1% - Financial News Network Online - Market Movers

May 9, 2013

SmarTrend Watching for Potential Pullback in Shares of Alexion Pharmaceuticals After 1.65% Gain - Comtex Smartrend(R)

May 9, 2013

Alexion to Present at the BofA Merrill Lynch 2013 Healthcare Conference - Businesswire

May 8, 2013

See All News Stories on ALXN

Broker Recommendations

Current ABR	1.45
ABR (Last Week)	1.45
# of recs in ABR	19
Average Target Price	116.25
Industry Rank by ABR	91 out of 265
Rank in Industry	4 out of 155

More ALXN Broker Recommendations

Day Low - High	101.77 - 104.29
52wk Low - High	81.82 - 119.54
Previous Close	101.82
Avg. Volume	1,765,227
Industry	MED-BIOMED/GENE
Market Cap	20.09 B
Div - Yield	0.00 - 0.00
Beta	0.47
PE (Forward)	38.58
Current Year Est.	2.67
Quarterly Earnings ESP	0.00%

PE (Forward)	38.58
PEG Ratio	1.51
Current Year Est.	2.67
Current Quarter Estimate	0.60
Most Accurate Estimate	0.60
Earnings ESP	0.00%
Next Earnings Report Date	07-24-2013
EPS Last Year	2.06
Expected Earnings Growth	25.52%

Username: Password:

Remember me [?]

Alexion Pharma: (NASD: ALXN)

$102.90

1.08 (1.06%)

Volume 977,654

May 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations